Acute myeloid leukemia (AML) remains un-targetable by new generation of immunotherapy like CAR-T cell therapy. Allogeneic HSC transfer (allo-HSCT) is a standard therapy for AML; however, allo-HSCT has the severe risk of inducing graft-versus-host disease (GvHD) side effect. Here we propose to develop an allogeneic HSC-iNKT cell therapy that has the potential to provide pro-GvL (graft-versus-leukemia) and anti-GvHD dual benefits when combined with allo-HSCT, and thereby significantly improve the current allo-HSCT therapy for treating AML.